No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
HK Stock MarketDetailed Quotes
06127 JOINN
- 8.760
- -0.240-2.67%
Market Closed Dec 20 16:08 CST
6.57BMarket Cap-8760.00P/E (TTM)
9.140High8.760Low1.09MVolume8.970Open9.000Pre Close9.64MTurnover0.91%Turnover Ratio14.97P/E (Static)749.48MShares14.30052wk High0.74P/B1.04BFloat Cap6.31052wk Low0.18Dividend TTM119.00MShs Float69.700Historical High0.180Dividend LFY4.22%Amplitude6.310Historical Low8.861Avg Price100Lot Size2.05%Div YieldTTM2.05%Div Yield LFY
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
JOINN Laboratories Announces Board Roles and Leadership
JOINN Laboratories Redirects Funds to Boost U.S. Operations
JOINN Laboratories Partners With Staidson for 2025 R&D Services
Joinn Laboratories (06127.HK) has entered into a research and development service agreement with Staidson for the year 2025.
On December 20, Gelonghui reported that Joinn Laboratories (06127.HK) announced that on December 20, 2024, the company entered into a 2025 research and development service framework agreement with Staidson, which will be effective from January 1, 2025, to December 31, 2025. The company is required to provide Staidson Group with comprehensive pharmaceutical research and development services covering non-clinical and clinical trial phases according to the 2025 Staidson research and development service framework agreement.
Joinn Laboratories (603127.SH): plans to contribute no more than 8 million yuan to set up the first phase of the Peking Fund.
On December 20, Gelonghui reported that Joinn Laboratories (603127.SH) announced that the company or its designated subsidiaries intend to sign a partnership agreement (hereinafter referred to as the "Partnership Agreement") with Peking Chongde Yingsheng Investment Management Co., Ltd. (hereinafter referred to as "Chongde Yingsheng"), Peking Huizhi Fu Technology Development Co., Ltd. (hereinafter referred to as "Huizhi Fu"), and Peking Guochao Super-Group Intelligent Technology Co., Ltd. (hereinafter referred to as "Guochao Super-Group") to participate in the investment in the Northern Brain Phase I Fund (hereinafter referred to as "this Fund"). This Fund plans to focus on brain science and mainly invest in areas such as the diagnosis and treatment of a new generation of neurological diseases.
Express News | The USA Biological Security Act was not included in the CR bill.
Trending HK Stocks
HK Crypto ETF HK Crypto ETF
An exchange-traded fund designed to track the price performance of Bitcoin or other major crypto, allowing investors to participate in the market without directly purchasing the assets.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in HK Crypto ETF, ranked from highest to lowest based on real-time market data. An exchange-traded fund designed to track the price performance of Bitcoin or other major crypto, allowing investors to participate in the market without directly purchasing the assets.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in HK Crypto ETF, ranked from highest to lowest based on real-time market data.
